A Study of DM005 in Patients With Advanced Solid Tumors
NCT06515990
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be a screening period of up to 28 days, a treatment period consisting of 21-day cycles, an end of treatment (EOT) Visit (+7 days), and a Follow-up Visit at 30 days (±7 days) after the EOT Visit.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- Solid Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Doma Biopharmaceutical（Suzhou）Co., Ltd.
- Last updated on ClinicalTrials.gov
- August 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Henry Ford Cancer Institute · Detroit, MI
Texas · 1
- Sarah Cannon Research Institute at Mary Crowley · Dallas, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.